IBU-TAB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IBU-TAB (IBU-TAB).
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
| Metabolism | Primarily hepatic via CYP2C9; also undergoes glucuronidation. Metabolites include hydroxy- and carboxy-ibuprofen, which are inactive. |
| Excretion | Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%. |
| Half-life | 2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain. |
| Protein binding | Approximately 99% bound to albumin. |
| Volume of Distribution | 0.1-0.3 L/kg. The low Vd indicates limited tissue distribution, primarily confined to plasma and extracellular fluid. |
| Bioavailability | Oral: 80-100% (well absorbed). Topical: approximately 5-10% systemically absorbed (varies with formulation and application site). |
| Onset of Action | Oral: 30-60 minutes for analgesic effect; peak effect at 1-2 hours. Topical: onset within 1-2 hours for local analgesia. |
| Duration of Action | Analgesic: 4-6 hours. Antipyretic: 6-8 hours. Note: Duration may be shorter with immediate-release formulations; sustained-release forms may extend to 12 hours. |
| Molecular Weight | 206.28 |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-60 mL/min: reduce dose by 50% and avoid in CrCl <30 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day. |
| Geriatric use | Initiate at lowest effective dose (e.g., 200 mg every 8-12 hours); monitor renal function and avoid long-term use. |
| 1st trimester | Avoid; associated with increased risk of miscarriage and congenital malformations (especially cardiac defects, gastroschisis). Use only if clearly needed and no alternative. |
| 2nd trimester | Caution; may cause oligohydramnios and fetal renal dysfunction. Use lowest effective dose for shortest duration. |
| 3rd trimester | Avoid; risk of premature closure of ductus arteriosus, oligohydramnios, neonatal renal impairment, and bleeding. |
Clinical note
Comprehensive clinical and safety monograph for IBU-TAB (IBU-TAB).
| Placental transfer | Placental transfer occurs; ibuprofen crosses the placenta. Cord blood concentrations are approximately 30% of maternal plasma levels. |
| Breastfeeding | Ibuprofen is excreted into breast milk in very low amounts (0.0008% of maternal dose). Considered compatible with breastfeeding; short-term use of lowest effective dose preferred. |
■ FDA Black Box Warning
NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsActive peptic ulcer disease or GI bleedingSevere renal impairment (CrCl <30 mL/min)Severe hepatic impairmentThird trimester of pregnancyKnown hypersensitivity to ibuprofen or any componentTreatment of perioperative pain in CABG surgery
| Precautions | Risk of serious GI adverse events including bleeding, ulceration, and perforation; NSAIDs should be used with caution in patients with history of peptic ulcer disease or GI bleeding. May cause renal toxicity, especially in patients with pre-existing renal impairment. Use with caution in patients with asthma, congestive heart failure, or hypertension. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | First trimester: Association with increased risk of miscarriage and congenital cardiac defects (odds ratio 1.86). Second/third trimester: Premature closure of ductus arteriosus, oligohydramnios, fetal renal impairment; avoid after 30 weeks gestation. Use not recommended during pregnancy. |
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and signs of bleeding (platelet function). Fetal ultrasound for ductus arteriosus patency and amniotic fluid volume if used late pregnancy. Assess for fetal growth restriction if chronic use. |
| Fertility Effects | Reversible impairment of female fertility via inhibition of prostaglandin synthesis, affecting ovulation and implantation. No known effect on male fertility. |
| Alcohol may increase risk of GI bleeding. Food delays absorption but does not significantly affect total exposure; take with food to improve tolerability. |
| Clinical Pearls | IBU-TAB (ibuprofen) is a non-selective COX inhibitor; use lowest effective dose for shortest duration to minimize GI and renal risks. Avoid in patients with NSAID-sensitive asthma, severe renal impairment (eGFR <30 mL/min), or perioperative pain in CABG surgery. Concomitant aspirin antagonizes irreversible antiplatelet effect; separate by 2 hours if immediate-release. Monitor for fluid retention and hypertension in cardiac patients. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not exceed 1200 mg/day without physician approval; higher doses increase risk of bleeding and kidney damage. · Avoid alcohol while taking this medication to reduce risk of stomach bleeding. · Discontinue and seek medical help if you experience signs of allergic reaction (rash, swelling, difficulty breathing) or black/tarry stools. · Inform your doctor about all medications you take, especially blood thinners, aspirin, other NSAIDs, and medications for blood pressure or kidney disease. |